| Literature DB >> 27803106 |
Shoumei Bai1, Patrick Ingram2, Yu-Chih Chen2, Ning Deng1, Alex Pearson1, Yashar S Niknafs1, Patrick O'Hayer1, Yun Wang1, Zhong-Yin Zhang3, Elisa Boscolo4, Joyce Bischoff5, Euisik Yoon2, Ronald J Buckanovich6,7.
Abstract
Little is known about the factors that regulate the asymmetric division of cancer stem-like cells (CSC). Here, we demonstrate that EGFL6, a stem cell regulatory factor expressed in ovarian tumor cells and vasculature, regulates ALDH+ ovarian CSC. EGFL6 signaled at least in part via the oncoprotein SHP2 with concomitant activation of ERK. EGFL6 signaling promoted the migration and asymmetric division of ALDH+ ovarian CSC. As such, EGFL6 increased not only tumor growth but also metastasis. Silencing of EGFL6 or SHP2 limited numbers of ALDH+ cells and reduced tumor growth, supporting a critical role for EGFL6/SHP2 in ALDH+ cell maintenance. Notably, systemic administration of an EGFL6-neutralizing antibody we generated restricted tumor growth and metastasis, specifically blocking ovarian cancer cell recruitment to the ovary. Together, our results offer a preclinical proof of concept for EGFL6 as a novel therapeutic target for the treatment of ovarian cancer. Cancer Res; 76(21); 6396-409. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27803106 PMCID: PMC5120866 DOI: 10.1158/0008-5472.CAN-16-0225
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701